ClinicalTrials.gg

Myotonic Dystrophy clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 126 studies for Myotonic Dystrophy across more than 10 countries. 50 are recruiting or about to start. 103 of them are mainly about Myotonic Dystrophy (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13.

Status

Completed
55
Recruiting
35
Enrolling by invitation
10
Status unknown
9
Active, not recruiting
8
Not yet recruiting
4

Phase

Phase 2
20
Phase 3
17
Phase 1
13

Where

United States
43
France
30
Canada
28
United Kingdom
22
Germany
20
Italy
19

Who develops what

Add Myotonic Dystrophy to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 7 programs from 5 companies, 6 with this as their studies’ main aim; 4 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Novartis, Sanofi and Vertex Pharmaceuticals here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
zeleciment basivarsen☆ Track1 live phase-3 study: NCT07486934Dyne Therapeutics
delpacibart zotadirsen☆ Track1 live phase-3 study: NCT07587242Novartis
AOC 1001☆ Track1 live phase-3 study: NCT07008469Novartis

The 3 in phase 3 with the nearest primary completion, of 7 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 2 Feb 2027 est.VX-670 · Vertex Pharmaceuticals Incorporated · Phase 2 main aimNCT06185764 A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) — primary endpoint: Parts A and B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) · 47 enrolled
  • Mar 2027 est.PGN-EDODM1 · PepGen Inc · Phase 2 main aimNCT06667453 A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 — primary endpoint: Safety and tolerability as assessed by number of participants with Adverse Events (AEs) · 24 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Myotonic Dystrophy studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

20studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 35 Myotonic Dystrophy studies recruiting now, 15 (43%) set no upper age limit and 18 (51%) stop at 75 or younger. 22 (63%) take children under 18. 2 (6%) are for women only and 2 (6%) for men only; 8 (23%) take healthy volunteers.

Recruiting studies that take each age, of 35
AgeWomenMen
1014 (40%)16 (46%)
1830 (86%)29 (83%)
3030 (86%)28 (80%)
4029 (83%)27 (77%)
5028 (80%)26 (74%)
6525 (71%)23 (66%)
7517 (49%)15 (43%)
8516 (46%)14 (40%)

Across all 126 studies, recruiting or not: 50% stop at 75 or younger and 40% at 65; 34% take children; 3% are for women only and 2% for men only; 26% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Myotonic Dystrophy studies take

Of 36 observational studies under Myotonic Dystrophy, half reached primary completion within 60 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Interventional, no phase23 mo12–57 · 25 studies——
Observational60 mo35–… · 36 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 126. Browse all 126 → or search them.